To Top

Archives for: May 31st, 2017

NORD Releases Statement on Orphan Drug Assessment & Pricing Summit

Written by on May 31, 2017

Washington, D.C., May 31, 2017—NORD released the following statement in advance of today’s “Orphan Drug Assessment and Pricing Summit” held by the Institute for Clinical and Economic Review (ICER):

“We are pleased to participate in ICER’s ‘Orphan Drug Assessment and Pricing Summit’, and look forward to providing the… Read More

Orphan Drug Act at 30: Will Success Become Too Expensive?

Written by on January 19, 2013

Reprinted with permission from FDA Matters:  By Steven Grossman

The Orphan Drug Act (ODA) turned 30 this month, demonstrating that good laws really can have an enduring impact.  Amidst the celebrations, a reporter asked me a provocative question:  Can we afford more orphan drugs costing hundreds of… Read More